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Introduction:
Each year in the U.S. more than a million men with an elevated serum PSA or abnormal digital rectal exam undergo a prostate biopsy, and nearly 200,000 are found to have prostate cancer (CaP). Decisions to treat CaP are heavily influenced by the Gleason score (GS) of the tumor in the needle biopsy specimen. Gleason score is a measure of tumor differentiation based on the two most prevalent patterns of tumor growth. Patients whose entire tumor is composed of GS6 rarely progress, and recently, more men diagnosed with GS6 tumors on needle biopsy are selecting active surveillance rather than surgery or radiation therapy. In contrast, men with more poorly differentiated tumors (GS7 and higher) have a significantly increased risk of progression, and require treatment.
Choosing the best treatment options for patients with biopsy GS6 is complicated by the fact that a biopsy procedure only samples a very small part of the prostate, and in about 30% of men, it underestimates the GS (1).
In those cases, men with GS7 and higher (GS7 + ) prostate cancer are assumed to have GS6 tumors potentially leading to inappropriate treatment. In addition, because of the limited sampling and 30% false negative rate for detecting cancer (2, 3), many men with a negative biopsy result may have clinically significant prostate cancer.
Because of that, many of the 800,000 patients with a negative biopsy undergo repeat biopsies which can be frustrating for both patients and urologists. When a pathologist examines a prostate needle biopsy specimen, the focus is on the identification of prostate cancer and appropriate Gleason scoring. Very little attention is paid to the "normal" areas which often comprise the majority of biopsy samples. This is despite a considerable body of evidence suggesting that molecular alterations associated with tumor in adjacent non-neoplastic cells, the so called "tumor field effect", can provide valuable clues regarding the status of the tumor. Remarkably, the field effect alterations have also been associated with aggressive prostate cancer (4).
Body / Results:
The objective is to develop clinically relevant molecular models to predict significant prostate cancer with GS7 + based on the prostate cancer field effect markers. This proposal will focus only on identification of significant tumors with GS7 + because Gleason score is the single strongest predictor of outcome in men with prostate cancer, and has the greatest influence on the clinical 
Research Accomplishments:
Select Table 3 describes samples with methylation sequencing data by RRBS. Both the RNA-seq (Table 2) and RRBS (Table 3 ) samples sizes are considerably larger than the initial study plans (Table 1) . We anticipate that the expansion of the discovery set will greatly improve the selection of robust field effect biomarkers which will be validated in subsequent steps.
Analysis -Mapping of methylated DNA and transcriptome data: MGF pipeline for mapping of sequence data has been used. These pipelines were established through a rigorous bioinformatics analyses (5) . Sequencing data for about 80% of the samples in tables 2 and 3 have been mapped.
The remaining 20% are in the queue for sequencing and once sequence data are made available will be mapped using the same programs.
Selection of transcriptomic markers: We have been developing de novo bioinformatics algorithm that focuses in identification of recurrent skipped exons that distinguish N 8+ from N i6 . These biomarkers can be incorporated in sensitive PCR assays where even small fractions of cells expressing the splice variants can be readily detected. Table 4 describes list of candidates selected using this algorithm. Additionally, Table 5 Quantitative PCR and methylation specific PCR: Several strategies for multiplex analyses of gene expression in FFPE samples were tested, including one-step and two-step RT-PCR, gene specific RT-PCR, and NanoString. At the end, the best performer was NanoString. With this technology, it was possible to produce results that were robust in less than 100 ng starting RNA (Figure 1 ). This sensitivity makes multiplexed gene-expression analyses in biopsies feasible as we typically obtained 100 ± 60 ng RNA (mean ± SD) by processing of the 2-3 sections of biopsy cores (data not shown).
Methylation specific PCR: A methylation specific PCR was developed and tested in FFPE samples for detection of GSTP1 methylation in prostate tumors (6) . The assay was remarkably sensitive and capable of detecting methylation changes in tumor compared with normal samples in starting material compatible with prostate biopsies (5-10ng in our experience).
Biopsy Case selection (Aim 1.c. and Aim 2): Under IRB guidance we identified the prostate cancer biopsies that are needed for this study in the Mayo Clinic archives. Seven types of biopsy samples will be acquired.
1. Last biopsies from patients with multiple negative biopsies; Aims Ic (n = 50) and IIb (n=70). Our search identified 2308 patients who have had at least 2 biopsies at the Mayo Clinic.
2. Negative cores of Gleason score 6 (GS6) biopsies from patients identified with insignificant GS6 tumors after surgeries; Aim Ic (n = 100). Our search identified 5460 patients with a GS6 biopsy. prostate needle biopsy and RP specimen Mayo database has been created for GS 6 tumors. This is comprised of 356 with an upgrading (GS>7) rate of 21% at RP. Upgrading occurs when the needle biopsy specimen is GS6 (and patient would be candidate for active surveillance) but RP specimen is GS7 or higher (indicating needle biopsy specimen sampling error). A separate more recent biopsy group is identified once again with paired biopsy and RP specimens at Mayo from 2010-2012 for validation work. This consists of 187 with an upgrading rate of 37%. Therefore 543 (356+187) patient biopsies have been characterized. We will characterize the remaining cases needed to reach 700.
6. Penultimate negative biopsies from patients identified with a GS6 cancer on the last biopsy; Aim IIb (n = 70). Our search identified 674 such patients.
7. Penultimate negative biopsies from patients identified with a GS7 and higher cancer on the last biopsy;
Aim IIb (n = 70). Our search identified 232 patients. In this group, 72 patients would be 85 years or older by the second year of the study based on their age at their first visit to the Mayo Clinic.
Additional related research activities:
In addition to the steps described above, we have engaged in other research activities which will enhance our abilities to accomplish PC100553 goals. These include:
Addition of a new member to the group: Prasuna Gupta, M.D. is a very diligent and excellent pathologist who is carefully going through the patients slides and selecting the right tissue blocks and biopsy cores for this project. Her contributions are invaluable to this research.
Genomic analyses of indolent and significant CaP: Based in our previous experience, field effect biomarkers can be robust if biomarker selection strategy is guided by changes in the corresponding tumor. In 2014, we secured a $50,000 award for generating transcriptome and epigenetic profiling of the iG6 and G7 + tumors. This study will also help in developing a model to predict upgrading of GS6 biopsies and complement models based on FE markers in the benign tissue. As shown in Tables 2 and 3 , we have close to 20 samples processed in each of significant and "indolent" tumor categories. Methylation and transcriptomic data from these samples are extremely valuable in guiding biomarker selection.
BPDE-DNA adducts as "field effect" biomarkers of "significant" prostate cancer: Previous studies by immunohistochemistry (IHC) have shown that the concentrations of BPDE-DNA adducts in the benign glands in prostate tissues that contain prostate cancer are correlated with the grade of prostate cancer (p = 0.008) (7) . Prostates that contain high grade of CaP had higher concentration of BPDE-DNA adducts in their benign glands compared with prostates that had low grades of CaP. Therefore, these adducts can serve as "field effect" biomarkers of "significant" prostate cancer. We obtained funding through an NIH R21 mechanism to develop protocols for measuring these adducts in human tissues including prostates. We now have these protocols worked out and are planning to test them in prostate samples in the coming year.
Pending external applications: In a collaborative effort with engineers in the University of Illinois at UrbanaChampaign (UIUC), we have applied for an R33 which received a good score and was resubmitted for further consideration. This grant aims to develop models for stratification of indolent from significant CaP at the biopsy stage. In these applications we plan to develop sensitive nano-scale IR resonators to identify different cell types in a prostate tissue, including reactive stroma and myofibroblast which are modified in the CaP by the field effect.
Additionally, selected biomarkers will be tested in a multiplexed fashion by quantum dots.
Collaboration with Dr. Thibodeau: Dr. Thibodeau at the Mayo Clinic also has a DOD award which requires transcriptome profiling of BP and N i6 and N 4+3 and has graciously agreed to share his data in this project. As shown in Table 2 , the additional samples through this collaboration will significantly enhance the number of samples for our analyses.
Un-anticipated events: In 2015, we spent efforts to test the new HiSeq4000 platform for RRBS and RNA-seq libraries. The new machine has significantly higher throughput than the previous generation (HiSeq2000) which allowed for multiplexing additional samples.
Reportable Outcomes
We have completed the most time consuming and challenging steps of this project which was the expanded sample collection for methylation and transcriptome sequencing. Additionally, we have prepared the DNA and RNA for almost the entire set of surgical validation cases and tested assays for the validation by gene expression and methylation experiments. Furthermore, through funding provided by the Clinomics program, we are in the final steps of sequencing "indolent" and "significant" tumor cases by RRBS and RNA-seq. Therefore, we are poised to harvest the results of a sizable set of data that we generated through the past years and we are confident that our selected candidate biomarkers will be incorporated in highly predictive models that can be applied to clinical settings.
We have reported on DNA rearrangements (such as translocations and deletions) in the CaP adjacent nonneoplastic cells in 2012 (8) . Another publication (9) describes our previous work related to the CaP field effect.
With the acknowledged support from this grant, this work was presented in the AACR meeting in April 2012.
Finally, we have applied for a major grant initiative which if funded, will help expanding the scope of this study through the use of nano-scale devices and quantum dot based assays.
Conclusions:
We expect to incorporate the sizable dataset generated in this work in several publications. The first one which we plan to submit by the end of this year will assess the similarities of HGPIN and tumor genomic abnormalities in patients with indolent and significant CaP. Sequencing data is mostly available and the analyses pipeline established. Therefore these results are expected to be available for publication shortly. The other publication will be incorporating our de novo bioinformatics program for identification of skipped junctions in prostate cancer field. Remaining step for this publication will be validation of markers selected in Table 4 .
We expect this manuscript to be submitted by early 2016. Finally, by the middle of 2016, we expect to have an integrated gene expression and methylation based biomarker models tested in biopsies for distinguishing indolent and significant cancers. We expect these models will be the subject of significant publications and more importantly of use in clinical settings.
